Basal/HER2 breast carcinomas: Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)

High rates of inherent primary resistance to the humanized monoclonal antibody trastuzumab (Herceptin) are frequent among HER2 gene-amplified breast carcinomas in both metastatic and adjuvant settings. The clinical efficacy of trastuzumab is highly correlated with its ability to specifically and eff...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Martin-Castillo, Begoña, Oliveras-Ferraros, Cristina, Vazquez-Martin, Alejandro, Cufí, Silvia, Moreno, José Manuel, Corominas-Faja, Bruna, Urruticoechea, Ander, Martín, Ángel G., López-Bonet, Eugeni, Menendez, Javier A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Landes Bioscience 2013
Gaiak:
Perspective
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3575452/
https://ncbi.nlm.nih.gov/pubmed/23255137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.23274
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak